119 related articles for article (PubMed ID: 35132321)
21. Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma.
Gao Y; Wang G; Chen Y; Zhang M; Gao W; Shang Z; Niu Y
Front Genet; 2022; 13():886983. PubMed ID: 35547260
[No Abstract] [Full Text] [Related]
22. Prognostic Implications and Immune Infiltration Analysis of ALDOA in Lung Adenocarcinoma.
Lu G; Shi W; Zhang Y
Front Genet; 2021; 12():721021. PubMed ID: 34925439
[No Abstract] [Full Text] [Related]
23. Prognostic value and potential function of splicing events in prostate adenocarcinoma.
Huang ZG; He RQ; Mo ZN
Int J Oncol; 2018 Dec; 53(6):2473-2487. PubMed ID: 30221674
[TBL] [Abstract][Full Text] [Related]
24. Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.
Zhao HB; Zeng YR; Han ZD; Zhuo YJ; Liang YK; Hon CT; Wan S; Wu S; Dahl D; Zhong WD; Wu CL
Cancer Sci; 2021 Oct; 112(10):4365-4376. PubMed ID: 34252262
[TBL] [Abstract][Full Text] [Related]
25. Correlation of IDH1 and B7H3 expression with prognosis of CRC patients.
Wu J; Wang F; Liu X; Zhang T; Liu F; Ge X; Mao Y; Hua D
Eur J Surg Oncol; 2018 Aug; 44(8):1254-1260. PubMed ID: 29871819
[TBL] [Abstract][Full Text] [Related]
26. Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.
Xu Y; Xu WH; Shi SN; Yang XL; Ren YR; Zhuang XY; Qu YY; Zhang HL; Zhang XF
J Cancer; 2020; 11(20):6101-6113. PubMed ID: 32922550
[No Abstract] [Full Text] [Related]
27. Comprehensive data analysis of genomics, epigenomics, and transcriptomics to identify specific biomolecular markers for prostate adenocarcinoma.
Ye C; Wang H; Li Z; Xia C; Yuan S; Yan R; Yang X; Ma T; Wen X; Yang D
Transl Androl Urol; 2021 Jul; 10(7):3030-3045. PubMed ID: 34430406
[TBL] [Abstract][Full Text] [Related]
28. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Laba P; Wang J; Zhang J
BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
[TBL] [Abstract][Full Text] [Related]
29. Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.
Deng X; Lin D; Chen B; Zhang X; Xu X; Yang Z; Shen X; Yang L; Lu X; Sheng H; Yin B; Zhang N; Lin J
Front Oncol; 2019; 9():1310. PubMed ID: 31824866
[TBL] [Abstract][Full Text] [Related]
30. AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma.
Ma C; Kang W; Yu L; Yang Z; Ding T
Front Oncol; 2020; 10():590006. PubMed ID: 33363020
[TBL] [Abstract][Full Text] [Related]
31. Multi-Omics Analysis Reveals Clinical Value and Possible Mechanisms of ATAD1 Down-Regulation in Human Prostate Adenocarcinoma.
Chen CC; Chu PY; Lin HY
Life (Basel); 2022 Oct; 12(11):. PubMed ID: 36362897
[TBL] [Abstract][Full Text] [Related]
32. Analysis of competing endogenous RNA network to identify the key RNAs associated with prostate adenocarcinoma.
Li Y; Yang Z
Pathol Res Pract; 2018 Nov; 214(11):1811-1817. PubMed ID: 30195637
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma.
Chen X; Li Q; Wang C; Xu W; Han L; Liu Y; Liu B; Guan S; Tan B; Wang J; Wang N; Song Q; Jia Y; Wang J; Zhao L; Cheng Y
Oncotarget; 2016 Dec; 7(52):86148-86160. PubMed ID: 27863386
[TBL] [Abstract][Full Text] [Related]
34. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
[TBL] [Abstract][Full Text] [Related]
35. Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability.
Liu WS; Chan SH; Chang HT; Li GC; Tu YT; Tseng HH; Fu TY; Chang HY; Liou HH; Ger LP; Tsai KW
Breast Cancer Res; 2018 Apr; 20(1):25. PubMed ID: 29661250
[TBL] [Abstract][Full Text] [Related]
36. Utilizing Ubiquitination Patterns to Predict Prostate Cancer Prognosis and Devise a Therapeutic Response.
Zhang X; Wang Y; Chang Y; Wang J; Yan S; Xiao Y; Guo T; Lou Y; Ma J; Xu W; Ren S
Arch Esp Urol; 2023 May; 76(3):215-231. PubMed ID: 37340527
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape.
Li S; Chen J; Chen X; Yu J; Guo Y; Li M; Pu X
Front Pharmacol; 2022; 13():997664. PubMed ID: 36110544
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
39. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
40. Identification and analysis of survival-associated ceRNA triplets in prostate adenocarcinoma.
Li F; Li H; Hou Y
Oncol Lett; 2019 Oct; 18(4):4040-4047. PubMed ID: 31579415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
